Device labelling review planned in Australia:
This article was originally published in Clinica
Australia's Therapeutic Devices Branch (TDB) is to undertake a review of the existing legislation covering labelling of medical devices, says the Australian Therapeutic Device Bulletin. Issues identified for consideration include sterility, pyrogenicity and warning statements relating to scheduled poisons or the observation of precautions. The TDB also believes there is a need to make more product information available to device users and consumers. Depending on the product, this information could include: instructions for use; explanation of possible risks/benefits; general warnings/precautions; set-up and check-out procedures; cleaning procedures; and maintenance, troubleshooting and storage information, the TDB suggests.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.